vs
GENMAB A/S（GMAB）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是Rollins, Inc.的1.0倍（$925.0M vs $906.4M），GENMAB A/S净利率更高（36.3% vs 11.9%，领先24.4%），GENMAB A/S同比增速更快（18.7% vs 10.2%），GENMAB A/S自由现金流更多（$327.0M vs $111.2M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
GMAB vs ROL — 直观对比
营收规模更大
GMAB
是对方的1.0倍
$906.4M
营收增速更快
GMAB
高出8.5%
10.2%
净利率更高
GMAB
高出24.4%
11.9%
自由现金流更多
GMAB
多$215.8M
$111.2M
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $906.4M |
| 净利润 | $336.0M | $107.8M |
| 毛利率 | 93.8% | — |
| 营业利润率 | 38.9% | 16.1% |
| 净利率 | 36.3% | 11.9% |
| 营收同比 | 18.7% | 10.2% |
| 净利润同比 | 65.5% | 2.5% |
| 每股收益（稀释后） | $5.42 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | — | $912.9M | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | $925.0M | $999.5M | ||
| Q1 25 | — | $822.5M | ||
| Q4 24 | — | $832.2M | ||
| Q3 24 | — | $916.3M | ||
| Q2 24 | $779.0M | $891.9M |
净利润GMABROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | — | $116.4M | ||
| Q3 25 | — | $163.5M | ||
| Q2 25 | $336.0M | $141.5M | ||
| Q1 25 | — | $105.2M | ||
| Q4 24 | — | $105.7M | ||
| Q3 24 | — | $136.9M | ||
| Q2 24 | $203.0M | $129.4M |
毛利率GMABROL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 93.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 96.4% | — |
营业利润率GMABROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | — | 17.5% | ||
| Q3 25 | — | 21.9% | ||
| Q2 25 | 38.9% | 19.8% | ||
| Q1 25 | — | 17.3% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | 30.3% | 20.4% |
净利率GMABROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | 36.3% | 14.2% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 12.7% | ||
| Q3 24 | — | 14.9% | ||
| Q2 24 | 26.1% | 14.5% |
每股收益（稀释后）GMABROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | $0.34 | ||
| Q2 25 | $5.42 | $0.29 | ||
| Q1 25 | — | $0.22 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.28 | ||
| Q2 24 | $3.13 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $5.3B | $1.4B |
| 总资产 | $6.5B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资GMABROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | — | $100.0M | ||
| Q3 25 | — | $127.4M | ||
| Q2 25 | $1.3B | $123.0M | ||
| Q1 25 | — | $201.2M | ||
| Q4 24 | — | $89.6M | ||
| Q3 24 | — | $95.3M | ||
| Q2 24 | $622.0M | $106.7M |
总债务GMABROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益GMABROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $5.3B | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | $4.4B | $1.2B |
总资产GMABROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $6.5B | $3.2B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | $5.6B | $2.8B |
负债/权益比GMABROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $111.2M |
| 自由现金流率自由现金流/营收 | 35.4% | 12.3% |
| 资本支出强度资本支出/营收 | 2.4% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.04× | 1.10× |
| 过去12个月自由现金流最近4个季度 | — | $621.1M |
8季度趋势，按日历期对齐
经营现金流GMABROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | — | $164.7M | ||
| Q3 25 | — | $191.3M | ||
| Q2 25 | $349.0M | $175.1M | ||
| Q1 25 | — | $146.9M | ||
| Q4 24 | — | $188.2M | ||
| Q3 24 | — | $146.9M | ||
| Q2 24 | $438.0M | $145.1M |
自由现金流GMABROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $182.8M | ||
| Q2 25 | $327.0M | $168.0M | ||
| Q1 25 | — | $140.1M | ||
| Q4 24 | — | $184.0M | ||
| Q3 24 | — | $139.4M | ||
| Q2 24 | $430.0M | $136.4M |
自由现金流率GMABROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | — | 17.4% | ||
| Q3 25 | — | 17.8% | ||
| Q2 25 | 35.4% | 16.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | — | 22.1% | ||
| Q3 24 | — | 15.2% | ||
| Q2 24 | 55.2% | 15.3% |
资本支出强度GMABROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 2.4% | 0.7% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | 1.0% | 1.0% |
现金转化率GMABROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | 1.04× | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | 2.16× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
ROL
暂无分部数据
